<DOC>
	<DOCNO>NCT00037128</DOCNO>
	<brief_summary>Lupus flare symptom associate systemic lupus erythematosus ( SLE ) may cause deficiency dehydroepiandrosterone ( DHEA ) . GL701 investigational new drug mean enhance DHEA level . This study design evaluate safety efficacy GL701 male lupus patient .</brief_summary>
	<brief_title>Study GL701 Men With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Inclusion Criteria Patient must diagnosis SLE &gt; 6 month accord 1989 revised ACR criterion . Patient must meet least four eleven ACR criterion systemic lupus Patient must modify SLEDAI score &gt; 3 screen qualify visit ( Appendix A2 ) Patient must treat SLE dose prednisone &lt; 30 mg/day ( include NO glucocorticoid therapy ) unchanged &gt; 6 week prior study entry ( include screen qualify visit ) . Prednisone dose patient 's receiving alternate day therapy mean daily prednisone dose Patient treat azathioprine , methotrexate , hydrochloroquine must stable dose change dose least 6 week precede study Patient must able read speak English willing sign inform consent English Exclusion Criteria Patient history prostate cancer Patient elevate Prostate Specific Antigen ( PSA ) Patient diagnose liver disease , define AST ALT &gt; 3x upper limit normal Patient ingest body building/anabolic steroid within last 6 month precede study Patient end stage renal disease receive hemodialysis treatment Patient serum creatinine &gt; 2 mg/dl creatinine clearance &lt; 60 ml/min Patient receive treatment ACTH within 3 month precede study entry Patient receiving androgen , immunoglobulin , cyclophosphamide , cyclosporin A , immunosuppressive agent , except azathioprine , methotrexate , hydrochloroquine within last 3 month Patient know hypersensitivity DHEA inactive ingredient use GL70l formulation ( cornstarch , lactose , magnesium stearate ) Patient participate prior DHEA study administration DHEA within past 3 month Patient use investigational agent within long 30 day 10 halflives agent Patient condition Investigator 's sponsor 's opinion sufficient prevent adequate compliance study likely confuse followup evaluation ( e.g.. alcoholism , drug addiction , acute withdrawal chemical dependency , psychiatric disease ) Patient require treatment/medication prohibit protocol Patient serious EKG abnormality determine Investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>Lupus</keyword>
	<keyword>SLE</keyword>
	<keyword>DHEA</keyword>
	<keyword>GL701</keyword>
</DOC>